Kraj: Irlandia
Język: angielski
Źródło: HPRA (Health Products Regulatory Authority)
Carprofen
Norbrook Laboratories (Ireland) Limited
QM01AE91
Carprofen
50 mg/tablet
Tablet
POM: Prescription Only Medicine as defined in relevant national legislation
carprofen
Authorised
2003-07-25
Health Products Regulatory Authority 25 June 2019 CRN0094PM Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carprieve 50 mg Tablets for Dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: _ACTIVE SUBSTANCE:_ Carprofen 50 mg _EXCIPIENTS:_ For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablets: A white/off white circular tablet with a break line on one face and 50 scored on the opposing face. The tablets can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For analgesia and reduction of chronic inflammation in musculoskeletal disturbances in dogs, for example in degenerative joint disease. 4.3 CONTRAINDICATIONS Use of this product in cats is contra-indicated.Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Refer to statements under Sections 4.3 and 4.5 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS: Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity. NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS: None. Health Products Regulatory Authority 25 June 2019 CRN0094PM Page 2 of 4 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) Typical undesirable effects associated with NSAIDs, such as vomiting, soft faeces/d Przeczytaj cały dokument